154 related articles for article (PubMed ID: 2451040)
1. Aromatase inhibition in the dog. II. Effect on growth, function, and pathology of the prostate.
Oesterling JE; Juniewicz PE; Walters JR; Strandberg JD; Steele RE; Ewing LL; Coffey DS
J Urol; 1988 Apr; 139(4):832-9. PubMed ID: 2451040
[TBL] [Abstract][Full Text] [Related]
2. Aromatase inhibition in the dog. I. Effect on serum LH, serum testosterone concentrations, testicular secretions and spermatogenesis.
Juniewicz PE; Oesterling JE; Walters JR; Steele RE; Niswender GD; Coffey DS; Ewing LL
J Urol; 1988 Apr; 139(4):827-31. PubMed ID: 2451039
[TBL] [Abstract][Full Text] [Related]
3. Effects of a new steroidal aromatase inhibitor, TZA-2237, and/or chlormadinone acetate on hormone-induced and spontaneous canine benign prostatic hyperplasia.
Ito K; Fukabori Y; Shibata Y; Suzuki K; Mieda M; Gotanda K; Honma S; Yamanaka H
Eur J Endocrinol; 2000 Oct; 143(4):543-54. PubMed ID: 11022202
[TBL] [Abstract][Full Text] [Related]
4. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.
Santen RJ; Demers LM; Lynch J; Harvey H; Lipton A; Mulagha M; Hanagan J; Garber JE; Henderson IC; Navari RM
J Clin Endocrinol Metab; 1991 Jul; 73(1):99-106. PubMed ID: 1646219
[TBL] [Abstract][Full Text] [Related]
5. The effect of inhibition of aromatase enzyme activity on Leydig cell number and ultrastructure in beagles.
Walters JR; Juniewicz PE; Oesterling JE; Mendis-Handagama SM; Zirkin BR; Ewing LL
Endocrinology; 1988 Nov; 123(5):2223-9. PubMed ID: 2971525
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of aromatase with CGS 16949A in postmenopausal women.
Santen RJ; Demers LM; Adlercreutz H; Harvey H; Santner S; Sanders S; Lipton A
J Clin Endocrinol Metab; 1989 Jan; 68(1):99-106. PubMed ID: 2521224
[TBL] [Abstract][Full Text] [Related]
7. Effects of the nonsteroidal aromatase inhibitor, Fadrozole, on sexual behavior in male rats.
Bonsall RW; Clancy AN; Michael RP
Horm Behav; 1992 Jun; 26(2):240-54. PubMed ID: 1535332
[TBL] [Abstract][Full Text] [Related]
8. Dihydrotestosterone concentration of beagle prostatic tissue: effect of age and hyperplasia.
Ewing LL; Berry SJ; Higginbottom EG
Endocrinology; 1983 Dec; 113(6):2004-9. PubMed ID: 6196180
[TBL] [Abstract][Full Text] [Related]
9. The new aromatase inhibitor CGS-16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro.
Lamberts SW; Bruining HA; Marzouk H; Zuiderwijk J; Uitterlinden P; Blijd JJ; Hackeng WH; De Jong FH
J Clin Endocrinol Metab; 1989 Oct; 69(4):896-901. PubMed ID: 2550511
[TBL] [Abstract][Full Text] [Related]
10. Effect of dual inhibition of 5-alpha-reductase and aromatase on spontaneously developed canine prostatic hypertrophy.
Suzuki K; Okazaki H; Ono Y; Kurokawa K; Suzuki T; Onuma E; Takanashi H; Mamiya Y; Yamanaka H
Prostate; 1998 Oct; 37(2):70-6. PubMed ID: 9759700
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A.
Steele RE; Mellor LB; Sawyer WK; Wasvary JM; Browne LJ
Steroids; 1987; 50(1-3):147-61. PubMed ID: 2973160
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effects of a nonsteroidal aromatase inhibitor (CGS 16949A) on 7, 12-dimethylbenz[alpha]anthracene-induced mammary tumors in rats.
Iino Y; Sugamata N; Owada S; Tago T; Sato H; Yokoe T; Maemura M; Morishita Y; Horiuchi R
Jpn J Clin Oncol; 1991 Jun; 21(3):153-9. PubMed ID: 1834875
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of CGS 16949A. A new aromatase inhibitor.
Lipton A; Harvey HA; Demers LM; Hanagan JR; Mulagha MT; Kochak GM; Fitzsimmons S; Sanders SI; Santen RJ
Cancer; 1990 Mar; 65(6):1279-85. PubMed ID: 2137721
[TBL] [Abstract][Full Text] [Related]
14. Novel aromatase inhibitors.
Bhatnagar AS; Häusler A; Schieweck K; Browne LJ; Bowman R; Steele RE
J Steroid Biochem Mol Biol; 1990 Nov; 37(3):363-7. PubMed ID: 2147860
[TBL] [Abstract][Full Text] [Related]
15. The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis.
Demers LM; Melby JC; Wilson TE; Lipton A; Harvey HA; Santen RJ
J Clin Endocrinol Metab; 1990 Apr; 70(4):1162-6. PubMed ID: 2156889
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effect of the aromatase inhibitor, anastrazole, to the antioestrogen, tamoxifen citrate, on canine prostate and semen.
Gonzalez G; Guendulain C; Maffrand C; Gobello C
Reprod Domest Anim; 2009 Jul; 44 Suppl 2():316-9. PubMed ID: 19754594
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of follicle stimulating hormone, luteinizing hormone, prolactin, testosterone, 5 alpha-dihydrotestosterone, 5 alpha-androstane-3 alpha, 17 beta-diol, 5 alpha-androstane-3 beta, 17 beta-diol, and 17 beta-estradiol from male beagles with spontaneous or induced benign prostatic hyperplasia.
Cochran RC; Ewing LL; Niswender GD
Invest Urol; 1981 Nov; 19(3):142-7. PubMed ID: 6170603
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of a specific aromatase inhibitor, 1-methyl-androsta-1,4-diene-3,17-dione (atamestane), in female rats bearing DMBA-induced mammary tumors.
Nishino Y; Schneider MR; Michna H; el Etreby MF
J Steroid Biochem; 1989; 34(1-6):435-7. PubMed ID: 2533949
[TBL] [Abstract][Full Text] [Related]
19. An in vitro method to determine the selective inhibition of estrogen biosynthesis by aromatase inhibitors.
Häusler A; Schenkel L; Krähenbühl C; Monnet G; Bhatnagar AS
J Steroid Biochem; 1989 Jul; 33(1):125-31. PubMed ID: 2527324
[TBL] [Abstract][Full Text] [Related]
20. Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease.
Browne LJ; Gude C; Rodriguez H; Steele RE; Bhatnager A
J Med Chem; 1991 Feb; 34(2):725-36. PubMed ID: 1825337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
